When atherosclerosis develops in the coronary arteries over a period of time, complete blockage of that artery can result in chest pain, shortness of breath and decreased quality of life.

A newly identified “atheroprotective” gene is a tool for exploring plaque pathophysiology and may be a good target for therapies to slow atherosclerosis progression.

Vanderbilt researchers have discovered a new target for the prevention of atherosclerotic plaque development and cardiovascular disease.

In some cases, HDL, the "good cholesterol," may not function properly and may actually accelerate atherosclerosis.

Vanderbilt University scientists have discovered a potential new strategy for lowering cholesterol and triglyceride levels and stopping atherosclerosis and fatty liver disease.

Compounds developed at Vanderbilt could offer a whole new way to treat atherosclerosis.